Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.66 |
| ▸ | CCNE2 | O96020 | 12/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.66 |
| ▸ | CDK2 | P24941 | 12/20 | 0.66 |
| ▸ | GSK3A | P49840 | 1/20 | 0.60 |
| ▸ | ATR | Q13535 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035526 | 0.95 | GSK3B (0.71) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034162 | 0.86 | GSK3B (0.67) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6599713 | 0.84 | MCHR1 (0.45) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034923 | 0.84 | GSK3B (0.56) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6033920 | 0.83 | ATR (0.85) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034153 | 0.82 | GSK3B (0.71) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034993 | 0.82 | GSK3B (0.65) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL27606610 | 0.81 | GSK3B (0.60) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034036 | 0.79 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034139 | 0.79 | GSK3B (0.73) | GSK3BCCNE2CCNE1CDK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | GSK3B 2/4885CCNE2 438/4885CCNE1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.